Study of new drug combo for untreated extensive-stage small cell lung cancer
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a new combination of drugs (QL1706, anti-angiogenesis therapy, and chemotherapy) for people with extensive-stage small cell lung cancer who have not received any prior treatment. The goal is to see if this combination works better than standard care.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must have extensive-stage small cell lung cancer that hasn't been treated yet.
- You should be at least 18 years old, with a life expectancy of 3 months or more.
- Your general health should be good enough to do normal daily activities (ECOG 0 or 1).
- You cannot have had prior chemotherapy, immunotherapy, or radiation for this cancer.
- You must be willing to provide a tumor sample (or have one available) and have at least one tumor that can be measured on scans.
- Your blood tests must show adequate organ function, and you cannot have certain active infections, autoimmune diseases, or severe heart problems.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests combining benmelstobart (a type of immunotherapy), anlotinib (a targeted blood vessel blocker), and standard chemotherapy as the very first treatment for extensive-stage small cell lung cancer (cancer that has spread widely). It aims to see if this combination works better than current options.
This trial tests a new combination treatment (ABBV-706 plus atezolizumab) as a first option for people with extensive stage small cell lung cancer. It compares this new approach to the usual standard treatment, aiming to see if it works better and has fewer side effects.
This trial tests a combination of four treatments—a new immunotherapy drug, an anti-cancer medication, chemotherapy, and targeted radiation—for people with extensive-stage small cell lung cancer that cannot be removed by surgery. The goal is to see if this combination can help control the cancer and improve survival.
This trial tests a new combination of drugs (chidamide, a PD-L1 inhibitor, carboplatin, and etoposide) as the first treatment for people with extensive-stage small-cell lung cancer. The goal is to see if this combination works better than standard treatments.
This study tests a combination of two drugs (QL1706 and bevacizumab) with or without chemotherapy for people with advanced non-squamous lung cancer whose cancer worsened after prior immunotherapy. It may offer a new option for those with low PD-L1 levels.
This trial tests a new study medicine, PF-08634404, combined with chemotherapy for people with extensive-stage small cell lung cancer. It aims to see if this combination works better than standard treatments.
Hear when a new Extensive Small Cell Lung Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.